TrialLancet (London, England)2022

Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial.

David M Gershenson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.